DEK

Summary

DEK (DEK proto-oncogene, HGNC:2768) is a protein-coding gene on chromosome 6p22.3, encoding Protein DEK (P35659). Involved in chromatin organization.

This gene encodes a protein with one SAP domain. This protein binds to cruciform and superhelical DNA and induces positive supercoils into closed circular DNA, and is also involved in splice site selection during mRNA processing. Chromosomal aberrations involving this region, increased expression of this gene, and the presence of antibodies against this protein are all associated with various diseases. Two transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 7913 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 64 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_003472

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:2768
Approved symbol	DEK
Name	DEK proto-oncogene
Location	6p22.3
Locus type	gene with protein product
Status	Approved
Aliases	D6S231E
Ensembl gene	ENSG00000124795
Ensembl biotype	protein_coding
OMIM	125264
Entrez	7913

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 20 protein_coding, 2 nonsense_mediated_decay, 2 retained_intron

ENST00000244776, ENST00000503715, ENST00000505224, ENST00000507591, ENST00000512145, ENST00000515742, ENST00000515770, ENST00000651624, ENST00000651992, ENST00000652292, ENST00000652576, ENST00000652689, ENST00000852487, ENST00000852488, ENST00000852489, ENST00000852490, ENST00000852491, ENST00000852492, ENST00000852493, ENST00000919563, ENST00000919564, ENST00000919565, ENST00000943458, ENST00000943459

RefSeq mRNA: 2 — MANE Select: NM_003472 NM_001134709, NM_003472

CCDS: CCDS34344, CCDS47382

Canonical transcript exons

ENST00000652689 — 11 exons

Exon	Start	End
ENSE00000848157	18226174	18226242
ENSE00000848158	18236452	18236600
ENSE00000848161	18256361	18256455
ENSE00000848162	18257953	18258062
ENSE00001642626	18263843	18263996
ENSE00001819650	18264385	18264530
ENSE00003515182	18255731	18255851
ENSE00003639492	18237381	18237516
ENSE00003670304	18249651	18249839
ENSE00003676421	18258304	18258405
ENSE00003851144	18223860	18225730

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 99.51.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 94.3530 / max 1399.2182, expressed in 1822 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
72043	73.0814	1818
72039	7.3240	1547
72037	5.1954	1384
72045	2.8369	1320
72041	1.6125	691
72046	1.3453	623
72032	1.3006	549
72042	0.5864	307
72040	0.5588	291
72038	0.3862	158

Top tissues by expression

302 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	99.51	gold quality
epithelium of nasopharynx	UBERON:0001951	99.28	gold quality
ventricular zone	UBERON:0003053	99.11	gold quality
tibia	UBERON:0000979	98.95	gold quality
ganglionic eminence	UBERON:0004023	98.84	gold quality
embryo	UBERON:0000922	98.55	gold quality
trabecular bone tissue	UBERON:0002483	98.54	gold quality
amniotic fluid	UBERON:0000173	98.53	gold quality
germinal epithelium of ovary	UBERON:0001304	98.53	gold quality
skin of hip	UBERON:0001554	98.20	gold quality
jejunal mucosa	UBERON:0000399	98.17	gold quality
endometrium epithelium	UBERON:0004811	98.17	gold quality
colonic epithelium	UBERON:0000397	98.09	gold quality
mammary duct	UBERON:0001765	97.96	gold quality
jejunum	UBERON:0002115	97.95	gold quality
mucosa of sigmoid colon	UBERON:0004993	97.85	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	97.79	gold quality
monocyte	CL:0000576	97.71	gold quality
visceral pleura	UBERON:0002401	97.70	gold quality
mononuclear cell	CL:0000842	97.69	gold quality
colonic mucosa	UBERON:0000317	97.68	gold quality
caecum	UBERON:0001153	97.68	gold quality
epithelium of mammary gland	UBERON:0003244	97.68	gold quality
parietal pleura	UBERON:0002400	97.65	gold quality
lower lobe of lung	UBERON:0008949	97.65	gold quality
pleura	UBERON:0000977	97.62	gold quality
cartilage tissue	UBERON:0002418	97.62	gold quality
vermiform appendix	UBERON:0001154	97.61	gold quality
palpebral conjunctiva	UBERON:0001812	97.60	gold quality
superficial temporal artery	UBERON:0001614	97.57	gold quality

Single-cell (SCXA)

Detected in 20 experiment(s), a significant marker in 15.

Experiment	Marker?	Max mean expression
E-CURD-122	yes	753.19
E-CURD-114	yes	69.76
E-HCAD-5	yes	46.34
E-CURD-112	yes	42.23
E-HCAD-10	yes	40.54
E-GEOD-125970	yes	24.59
E-HCAD-13	yes	22.41
E-CURD-46	yes	21.80
E-HCAD-1	yes	19.64
E-MTAB-10042	yes	10.56
E-MTAB-10553	yes	9.43
E-CURD-88	yes	9.40
E-MTAB-6678	yes	8.47
E-HCAD-11	yes	7.34
E-CURD-53	no	1198.79

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

5 targets.

Target	Regulation
BCL2	Activation
BIRC3	Unknown
CXCL8	Unknown
HLA-DQB1	Unknown
PRDX5	Repression

Upstream regulators (CollecTRI, top): NFKB, TFAP2A, YY1

miRNA regulators (miRDB)

157 targeting DEK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-656-3P	100.00	72.15	2788
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-3924	100.00	72.09	2394
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-551B-5P	99.96	71.28	3493

Literature-anchored findings (GeneRIF, showing 40)

• overexpressed in acute myeloid leukemia while translocations associated with this gene are absent (PMID:12031912)
• Data show that Daxx associates with proteins critical for transcriptional repression, such as histone deacetylase 2 and Dek, a chromatin-associated protein reported to change the topology of DNA in chromatin in vitro. (PMID:12140263)
• interacts with latency-associated nuclear antigen of Kaposi’s sarcoma-associated herpesvirus (KSHV) to tether KSHV to cell chromosomes (PMID:12388720)
• analysis of regulation by mapping discrete elements within the proximal promoter that are responsible for constitutive transcription of dek in transformed cells (PMID:12483538)
• overexpression of DEK is associated with acute myeloid leukemia (PMID:14738146)
• C-terminal domain (amino acids 270 to 350)is able to multimerize, dependent on phosphorylation by CK2 kinase; two DNA-interacting domains differing in their binding properties and in their abilities to respond to CK2 phosphorylation were found (PMID:15199153)
• found evidence that DEK is phosphorylated by CK2, phosphorylation sites are clustered in the C-terminal region, phosphorylated DEK is tethered to chromatin throughout the cell cycle by the un- or underphosphorylated form of DEK. (PMID:15199154)
• Could function as an architectural protein in chromatin comparable to the better known classic architectural chromatin proteins, the high-mobility group or HMG proteins. (PMID:15563827)
• Evidence for an rheumatoid arthritis susceptibility locus mapping under the linkage peak on 6p, 11 Mb telomeric of HLA-DRB1 implicates the gene DEK. (PMID:15593216)
• The DNA binding properties of the SAF-box domain of DEK. (PMID:15722484)
• results suggest that DEK and E2F3 are potential targets of 6p gains in retinoblastoma (PMID:16007192)
• The 6p22 genomic gain present in many retinoblastoma tumors leads to DEK overexpression at the mRNA and protein level. (PMID:16180235)
• repression of DEK message and protein levels in senescing human papillomavirus type 16- (HPV16-) and HPV18-positive cancer cell lines as well as in primary cells undergoing replicative senescence. (PMID:16254365)
• DEK interacts with histones and exerts a potent inhibitory effect on both p300 and PCAF-mediated histone acetyltransferase activity and transcription. (PMID:16696975)
• DEK is overexpressed in many solid tumors such as colon cancer, larynx cancer, bladder cancer, and melanoma; the DEK promoter is bound by endogenous E2F in vivo (PMID:16721057)
• DEK enforces 3’ splice site discrimination by U2AF; DEK phosphorylated at serines 19 and 32 associates with U2AF35, facilitates the U2AF35-AG interaction and prevents binding of U2AF65 to pyrimidine tracts not followed by AG (PMID:16809543)
• DEK functions to negatively regulate transcription of RelA/p65 (PMID:16829531)
• suggest a novel role for DEK in cellular survival, involving the destabilization of p53 in a manner which is likely to contribute to human carcinogenesis (PMID:16894028)
• DEK can play a direct role in inflammation by attracting neutrophils, CD8-positive T cells, and natural killer cells. (PMID:17030615)
• Our conclusion is that DEK could serve as an architectural protein at the promoter or enhancer sites of a subfraction of human genes. (PMID:17524367)
• acidic domain containing protein DEK might have a role in modulating both transcriptional regulation and apoptosis through HAT inhibitory activity. (PMID:17685435)
• description of the three-dimensional structure of the N-terminal domain of DEK as determined using solution NMR; study illustrates a new structural variant and reveals novel dsDNA-binding properties for proteins containing the SAP/SAF motif (PMID:18227428)
• DEK promotes the repair of DNA lesions and protects cells from genotoxic agents that typically trigger poly(ADP-ribose) polymerase activation. (PMID:18332104)
• DEK plays an important role in the carcinogenesis of cervical cancers, helpful for early diagnosis, and potential therapeutic target. (PMID:18477217)
• DEK up-regulation may contribute to carcinoma development at least in part through increased proliferation and retardation of differentiation. (PMID:19036808)
• Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo. (PMID:19223548)
• Data demonstrate the modulation of caspase-dependent apoptosis related proteins by DEK knock-down and further implicate its role in apoptosis pathway. (PMID:19229864)
• DEK plays an important role in the progression of ovarian serous cancers (PMID:19563407)
• DEK is a long sought-after oncogene mapping at chromosome 6, with novel functions in melanoma proliferation and chemoresistance. (PMID:19679545)
• In some human myeloid leukemia patients, DEK was fused to CAN by chromosomal translocation (PMID:20040570)
• The oncogene DEK promotes leukemic cell survival and is downregulated by both Nutlin-3 and chlorambucil in B-chronic lymphocytic leukemic cells. (PMID:20215548)
• Here we will summarize the current literature about the regulation and function(s) of DEK as a proto-oncogene. (PMID:20501624)
• DEK overexpression, partly through an increase in its gene dose, mediates the activity of global transcriptional regulators and is associated with tumor initiation activity and poor prognosis in high grade neuroendocrine carcinoma of the lung. (PMID:20543864)
• Using sequence alignment, the study identifies three functional poly(ADP-ribose)-binding sites in the DEK primary sequence and confirms their functionality in poly(ADP-ribose) binding studies. (PMID:20669926)
• DEK can contribute directly to joint inflammation in juvenile idiopathic arthritis by generating ICs through high-affinity interaction between DEK and DEK autoantibodies. (PMID:21280010)
• DEK overexpression may be a frequent event in invasive melanomas, and further augmentation of DEK expression may be associated with the acquisition of ominous features such as deep dermal invasion and metastasis. (PMID:21316078)
• data indicate that DEK expression stimulates the growth, stem cell character and motility of breast cancer cells, and that DEK-dependent cellular invasion occurs at least in part via beta-catenin activation (PMID:21317931)
• identify the oncoprotein DEK, an abundant nuclear protein with a previously enigmatic in vivo function, as a Suppressor of Variegation [Su(var)] that is crucial to global heterochromatin integrity (PMID:21460035)
• DEK is important for DNA double-strand break repair. (PMID:21653549)
• DEK protein is expressed in bladder tumor tissue and voided urine of bladder cancer patients. (PMID:21663673)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	dek	ENSDARG00000070108
mus_musculus	Dek	ENSMUSG00000021377
rattus_norvegicus	Dek	ENSRNOG00000016152
drosophila_melanogaster	Dek	FBGN0026533

Protein

Protein identifiers

Protein DEK — P35659 (reviewed: P35659)

All UniProt accessions (8): A0A494C028, A0A494C198, B4DFG0, D6R9L5, D6RDA2, P35659, H0Y8X0, H0Y993

UniProt curated annotations — full annotation on UniProt →

Function. Involved in chromatin organization.

Subunit / interactions. Found in a mRNA splicing-dependent exon junction complex (EJC) with DEK, RBM8A, RNPS1, SRRM1 and ALYREF/THOC4. Interacts with histones H2A, H2B, H3, H4, acetylated histone H4, non-phosphorylated DAXX and HDAC2. Component of the B-WICH complex, at least composed of SMARCA5/SNF2H, BAZ1B/WSTF, SF3B1, DEK, MYO1C, ERCC6, MYBBP1A and DDX21. Binds DNA.

Subcellular location. Nucleus.

Tissue specificity. Ubiquitous. Expressed at relatively high levels.

Post-translational modifications. Phosphorylated by CK2. Phosphorylation fluctuates during the cell cycle with a moderate peak during G(1) phase, and weakens the binding of DEK to DNA.

Disease relevance. A chromosomal aberration involving DEK is found in a subset of acute myeloid leukemia (AML); also known as acute non-lymphocytic leukemia. Translocation t(6;9)(p23;q34) with NUP214/CAN. It results in the formation of a DEK-NUP214 fusion gene.

Isoforms (2)

UniProt ID	Names	Canonical?
P35659-1	1	yes
P35659-2	2

RefSeq proteins (2): NP_001128181, NP_003463* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003034	SAP_dom	Domain
IPR014876	DEK_C	Domain
IPR044198	DEK	Family

Pfam: PF02037, PF08766

UniProt features (62 total): modified residue 31, helix 10, compositionally biased region 7, domain 2, DNA-binding region 2, strand 2, region of interest 2, initiator methionine 1, chain 1, splice variant 1, sequence variant 1, turn 1, short sequence motif 1

Structure

Experimental structures (PDB)

6 structures.

PDB	Method	Resolution (Å)
9L1X	ELECTRON MICROSCOPY	2.69
8KCY	ELECTRON MICROSCOPY	2.8
9L22	ELECTRON MICROSCOPY	3
8KD1	ELECTRON MICROSCOPY	3.2
1Q1V	SOLUTION NMR
2JX3	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P35659-F1	66.18	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (31): 2, 13, 15, 19, 32, 51, 72, 121, 122, 159, 199, 201, 204, 210, 227, 230, 231, 232, 243, 244 …

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-5250924	B-WICH complex positively regulates rRNA expression
R-HSA-8864260	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
R-HSA-9616222	Transcriptional regulation of granulopoiesis

MSigDB gene sets: 308 (showing top): GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, MORF_SMC1L1, STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, MORF_UBE2I, GEORGES_CELL_CYCLE_MIR192_TARGETS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, MORF_HDAC1, MORF_RAD21, GOBP_TRANSCRIPTION_BY_RNA_POLYMERASE_III, MORF_CDK2, MITSIADES_RESPONSE_TO_APLIDIN_DN, MORF_HDAC2, GNF2_MCM5, GOBP_REGULATION_OF_DNA_REPAIR, DOANE_BREAST_CANCER_CLASSES_DN

GO Biological Process (11): chromatin remodeling (GO:0006338), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), signal transduction (GO:0007165), viral genome replication (GO:0019079), positive regulation of transcription by RNA polymerase I (GO:0045943), positive regulation of transcription by RNA polymerase II (GO:0045944), positive regulation of transcription by RNA polymerase III (GO:0045945), regulation of double-strand break repair (GO:2000779), regulation of double-strand break repair via nonhomologous end joining (GO:2001032), chromatin organization (GO:0006325)

GO Molecular Function (4): DNA binding (GO:0003677), RNA binding (GO:0003723), histone binding (GO:0042393), protein binding (GO:0005515)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), nucleolus (GO:0005730), contractile muscle fiber (GO:0043292), B-WICH complex (GO:0110016)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Positive epigenetic regulation of rRNA expression	1
Generic Transcription Pathway	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of DNA-templated transcription	3
transcription by RNA polymerase II	2
nucleic acid binding	2
nuclear lumen	2
intracellular membraneless organelle	2
chromatin organization	1
regulation of DNA-templated transcription	1
DNA-templated transcription	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
viral process	1
viral life cycle	1
regulation of transcription by RNA polymerase I	1
transcription by RNA polymerase I	1
regulation of transcription by RNA polymerase II	1
regulation of transcription by RNA polymerase III	1
transcription by RNA polymerase III	1
regulation of DNA repair	1
double-strand break repair	1
double-strand break repair via nonhomologous end joining	1
regulation of double-strand break repair	1
cellular component organization	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1
cytoplasm	1
supramolecular fiber	1
nucleolus	1
SWI/SNF superfamily-type complex	1

Protein interactions and networks

STRING

2134 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DEK	RNPS1	Q15287	972
DEK	SRRM1	Q8IYB3	968
DEK	NUP214	P35658	928
DEK	U2AF1	Q01081	898
DEK	ALYREF	Q86V81	876
DEK	U2AF2	P26368	833
DEK	DAXX	Q9UER7	708
DEK	H2AC20	Q16777	700
DEK	H2BC21	Q16778	676
DEK	MYBBP1A	Q9BQG0	668
DEK	ANP32A	P39687	658
DEK	SRSF11	Q05519	650
DEK	JMJD6	Q6NYC1	650
DEK	PNN	Q9H307	649
DEK	KMT2A	Q03164	629

IntAct

85 interactions, top by confidence:

A	B	Type	Score
CDK8	MED19	psi-mi:“MI:0914”(association)	0.850
PHF1	EED	psi-mi:“MI:0914”(association)	0.790
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
ARHGEF26	CASK	psi-mi:“MI:0914”(association)	0.690
DEK	CSNK2A1	psi-mi:“MI:0217”(phosphorylation reaction)	0.690
LCOR	PHF1	psi-mi:“MI:0914”(association)	0.640
DEK	GPATCH11	psi-mi:“MI:0915”(physical association)	0.560
ULK3	AIP	psi-mi:“MI:0914”(association)	0.530
DAXX	DEK	psi-mi:“MI:0915”(physical association)	0.500
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
H3C1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.410
UBE2K	DEK	psi-mi:“MI:0915”(physical association)	0.400
KIF13B	DEK	psi-mi:“MI:0915”(physical association)	0.400
KIF15	DEK	psi-mi:“MI:0915”(physical association)	0.400
DEK	H2BC9	psi-mi:“MI:0915”(physical association)	0.400
DHX16	DEK	psi-mi:“MI:0915”(physical association)	0.400
UPF1	DEK	psi-mi:“MI:0915”(physical association)	0.400
MAF1b1	DEK	psi-mi:“MI:0915”(physical association)	0.370
Rpl35	RPS6	psi-mi:“MI:0914”(association)	0.350
RPL10	RPS6	psi-mi:“MI:0914”(association)	0.350
NOP56	C12orf43	psi-mi:“MI:0914”(association)	0.350
MMGT1	DERL1	psi-mi:“MI:0914”(association)	0.350
RBPJ	SAMD1	psi-mi:“MI:0914”(association)	0.350
JUN		psi-mi:“MI:0914”(association)	0.350
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350

BioGRID (280): SPOP (Affinity Capture-Western), DEK (Protein-peptide), DEK (Biochemical Activity), DEK (Affinity Capture-Western), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS), BPTF (Co-fractionation), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS), DEK (Affinity Capture-MS)

ESM2 similar proteins: F4JP52, F4JW79, F4K4D6, F4K4Y5, I1HNB2, O04608, O23063, O24591, O48802, O49595, P05221, P06748, P07222, P13084, P16039, P35659, P91753, Q0WNR6, Q1HTZ8, Q1HTZ9, Q1PEP5, Q3T160, Q56WH4, Q61937, Q63ZM9, Q6AXS3, Q6DJ13, Q6V9I6, Q7TNV0, Q7XTT4, Q84JB7, Q8GUP3, Q8LDF9, Q8LJS2, Q8RXT5, Q94C59, Q94IK2, Q9C8J7, Q9FVE6, Q9H501

Diamond homologs: P35659, Q6AXS3, Q7TNV0, Q84JB7, Q9SMM8, F4K4Y5, Q9SUA1

SIGNOR signaling

15 interactions.

A	Effect	B	Mechanism
CSNK2A1	up-regulates	DEK	phosphorylation
DEK	“down-regulates quantity by repression”	PRDX5	“transcriptional regulation”
DEK	“form complex”	“B-WICH complex”	binding
SPOP	“down-regulates quantity by destabilization”	DEK	binding
“Cullin 3-RBX1-Skp1”	“down-regulates quantity by destabilization”	DEK	ubiquitination
GSK3B	“down-regulates quantity by destabilization”	DEK	phosphorylation
SCF-FBW7	“down-regulates quantity by destabilization”	DEK	polyubiquitination

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
PRC2 methylates histones and DNA	5	9.6×	8e-03
Regulation of PD-L1(CD274) transcription	6	8.3×	7e-03
NoRC negatively regulates rRNA expression	6	8.0×	7e-03
Activation of anterior HOX genes in hindbrain development during early embryogenesis	6	6.9×	1e-02
mRNA Splicing - Major Pathway	8	5.5×	7e-03
Dengue Virus-Host Interactions	9	5.2×	7e-03

GO biological processes:

GO term	Partners	Fold	FDR
stem cell population maintenance	5	22.4×	2e-03
JNK cascade	5	14.5×	9e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

64 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	49
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1773 predictions. Top by Δscore:

Variant	Effect	Δscore
6:18225727:TTAG:T	acceptor_gain	1.0000
6:18236447:ATTAC:A	donor_loss	1.0000
6:18236448:TTA:T	donor_loss	1.0000
6:18236449:TA:T	donor_loss	1.0000
6:18236450:A:AT	donor_loss	1.0000
6:18236451:C:A	donor_loss	1.0000
6:18236597:CTTT:C	acceptor_gain	1.0000
6:18236601:C:CC	acceptor_gain	1.0000
6:18237377:ATAC:A	donor_loss	1.0000
6:18237378:TAC:T	donor_loss	1.0000
6:18237379:A:AC	donor_gain	1.0000
6:18237379:ACCT:A	donor_loss	1.0000
6:18237380:C:CC	donor_gain	1.0000
6:18237512:GGTGG:G	acceptor_gain	1.0000
6:18237513:GTGG:G	acceptor_gain	1.0000
6:18237514:TGG:T	acceptor_gain	1.0000
6:18237515:GG:G	acceptor_gain	1.0000
6:18237515:GGC:G	acceptor_loss	1.0000
6:18237516:GC:G	acceptor_loss	1.0000
6:18237517:C:CA	acceptor_loss	1.0000
6:18237517:C:CC	acceptor_gain	1.0000
6:18237519:G:C	acceptor_gain	1.0000
6:18237520:T:C	acceptor_gain	1.0000
6:18237520:T:TC	acceptor_gain	1.0000
6:18237523:C:CT	acceptor_gain	1.0000
6:18237524:A:T	acceptor_gain	1.0000
6:18244604:C:CC	acceptor_gain	1.0000
6:18249645:TTTTA:T	donor_loss	1.0000
6:18249646:TTTAC:T	donor_loss	1.0000
6:18249647:TTAC:T	donor_loss	1.0000

AlphaMissense

2518 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:18255758:G:C	F182L	1.000
6:18255758:G:T	F182L	1.000
6:18255760:A:G	F182L	1.000
6:18255813:A:G	L164P	1.000
6:18255821:A:C	C161W	1.000
6:18256418:C:T	G132D	1.000
6:18256419:C:G	G132R	1.000
6:18256423:G:C	F130L	1.000
6:18256423:G:T	F130L	1.000
6:18256424:A:G	F130S	1.000
6:18256425:A:G	F130L	1.000
6:18257957:C:T	G118D	1.000
6:18257982:G:C	H110D	1.000
6:18257993:A:G	L106P	1.000
6:18258354:A:G	L66S	1.000
6:18258356:C:A	R65S	1.000
6:18258356:C:G	R65S	1.000
6:18258377:C:A	R58S	1.000
6:18258377:C:G	R58S	1.000
6:18258378:C:A	R58M	1.000
6:18258378:C:G	R58T	1.000
6:18255747:G:T	P186Q	0.999
6:18255813:A:T	L164H	0.999
6:18255822:C:T	C161Y	0.999
6:18255834:A:G	L157S	0.999
6:18256408:A:C	F135L	0.999
6:18256408:A:T	F135L	0.999
6:18256410:A:G	F135L	0.999
6:18256414:A:C	F133L	0.999
6:18256414:A:T	F133L	0.999

dbSNP variants (sampled 300 via entrez): RS1000016996 (6:18243732 G>A), RS1000036179 (6:18224186 T>C), RS1000097076 (6:18228898 C>G), RS1000190947 (6:18264721 G>A,C,T), RS1000205166 (6:18259061 T>C), RS1000220251 (6:18264868 C>A,G), RS1000292117 (6:18233345 A>G), RS1000307917 (6:18238754 C>T), RS1000349909 (6:18224424 CAT>C), RS1000408671 (6:18264061 AC>A), RS1000420609 (6:18238447 C>A,G,T), RS1000493317 (6:18227324 G>A,C), RS1000496853 (6:18232358 G>A), RS1000521731 (6:18244021 T>A,C), RS1000597714 (6:18248629 A>C,G)

Disease associations

OMIM: gene MIM:125264 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST006414_141	Atrial fibrillation	2.000000e-19
GCST009391_1568	Metabolite levels	4.000000e-06
GCST009391_533	Metabolite levels	3.000000e-06
GCST009391_598	Metabolite levels	1.000000e-07
GCST010320_13	PR interval	5.000000e-10
GCST010321_8	PR interval	1.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0010516	orotic acid measurement
EFO:0010528	quinolinic acid measurement
EFO:0010502	indoxyl sulfate measurement
EFO:0004462	PR interval

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6066180 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,538 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1232461	MOLIBRESIB	2	1,538

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

1 potent at pChembl≥5 of 1 total, top 1 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.43	IC50	3690	nM	MOLIBRESIB

PubChem BioAssay actives

1 with measured affinity, of 6 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(4S)-6-(4-chlorophenyl)-8-methoxy-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepin-4-yl]-N-ethylacetamide	2178831: Inhibition of DEK (unknown origin) incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	ic50	3.6900	uM

CTD chemical–gene interactions

88 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression	3
perfluorooctane sulfonic acid	decreases expression	2
Resveratrol	affects cotreatment, increases expression, decreases expression	2
Doxorubicin	decreases expression, increases expression	2
Quercetin	affects phosphorylation, decreases expression	2
Cyclosporine	decreases expression, increases expression	2
Aflatoxin B1	affects expression, decreases methylation	2
Cadmium Chloride	decreases expression, increases expression, increases methylation	2
Particulate Matter	decreases expression, increases abundance	2
aristolochic acid I	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	decreases sumoylation	1
dicrotophos	decreases expression	1
2,4,6-tribromophenol	increases expression	1
triphenyl phosphate	affects expression	1
geraniol	decreases expression	1
sodium arsenate	decreases expression	1
titanium dioxide	affects expression	1
decabromobiphenyl ether	increases expression	1
kojic acid	decreases expression	1
trichostatin A	affects expression	1
alpha-ketoisocaproic acid	decreases chemical synthesis, decreases secretion	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
tetrabromobisphenol A	increases expression	1
N(1)-methylnicotinamide	decreases chemical synthesis	1
coumarin	increases phosphorylation	1
formic acid	decreases chemical synthesis	1
dimethylamine	increases secretion	1

ChEMBL screening assays

6 unique, capped per target: 6 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5697561	Binding	Inhibition of DEK (unknown origin) assessed as fold change at 10 uM incubated for 1 hr by colloidal coomassie staining based LC-MS/MS analysis	Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. — Nature

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_2041	FKH-1	Cancer cell line	Male
CVCL_5058	SNU-407	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.